Trending Stories on Eyewire+
EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMD
EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD).
Duravyu is an investigational therapy that uses a proprietary bioerodible Durasert E?platform to deliver... Read More
Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMD
The UK’s National Institute for Health and Care Excellence (NICE) has recommended?Lytenava?(bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for?Lytenava?worldwide and supports its commercialization strategy in the United Kingdom and Europe.
Lytenava?is the first authorized ophthalmic formulation of bevacizumab for wet AMD in the European Union (EU) and the UK, where it enjoys 10 years of... Read More
UC Irvine Scientists Find DNA Damage is Key Factor in AMD
Accumulated DNA damage in the retina is a key contributor to age-related macular degeneration (AMD) and targeting specific retinal cell types may lead to treatments that slow or stop progression, according to a?research team co-led by the University of California, Irvine.
The study, recently published online in the journal?Aging Cell,?reveals how... Read More
EyewireTV | 12.04.2024
A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL?Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Click here to check it out!
Latest In Podcasts
领英推荐
Detecting, Quantifying, and Managing HOAs
Cecelia Koetting, OD, FAAO, Dipl ABO, closes out The MOD Pod's last episode of 2025 with a discussion on aberrations in refractive cataract surgery with Nick Bruns, OD, FAAO. With modern technology, Dr. Bruns emphasizes that understanding the effect of higher-order aberrations helps optometrists better achieve optimal outcomes. Click here to catch the latest episode.
Case Review: Hemifacial Spasm
In this case, a 55-year-old man presented with an uncontrollable spasm on the right side of his face. Sila Bal, MD, invites oculofacial surgeon Julie Woodward, MD, to explain how she would approach the examination of this patient, describing the questions she would ask to obtain a detailed family and medical history and determine if the condition is a hemifacial spasm, blepharospasm, or myokymia. Catch the latest episode here!
Eyewire News: The Podcast
A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL?Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Catch the latest episodes here!
Latest in Subspecialties:
Thank you for reading! We'll be back next week with another edition of?Eyewire+ Weekly Digest. For the most up to date news, please visit us at Eyewire+.